Learn how we write papers to push representatives into taking action
All of our papers are made with the hard work of many individuals, all with the goal to cause change that will make the world a better place.
Policy Paper Authors
People Impacted Across 10+ Countries
Our Authors work hard to write these papers, with mulitple of them reaching places such as the EU.
This paper explores how the European Union’s Critical Medicines Act (CMA) can secure the supply of recombinant vaccines, which are vital for pandemics, routine immunization, and cancer prevention but vulnerable to supply chain disruptions. It proposes five key strategies: updating the critical medicines list regularly, prioritizing vaccines based on risk, supporting sustainable manufacturing, building an EU biofoundry network, and conducting routine stress tests. Together, these measures aim to make Europe’s vaccine supply more resilient, sustainable, and reliably accessible to all citizens.
This paper examines the EU’s Joint Clinical Assessment (JCA) initiative, which streamlines clinical evaluation of medical devices, including recombinant vaccines, to reduce duplication and accelerate approvals across member states. It highlights seven recommendations—structured consultations, balanced report authority, clinician input, improved accessibility, patient feedback, a digital collaboration platform, and public education—to make JCAs more transparent, inclusive, and effective, ensuring innovative therapies reach patients fairly and efficiently.
This paper explains the EU’s Joint Clinical Assessment (JCA) initiative, which streamlines clinical evaluation of medical devices—including recombinant vaccines—across member states. By reducing duplication and speeding approvals, JCAs improve equitable access. Seven recommendations—from structured consultations to digital collaboration and public education—aim to make JCAs more transparent, inclusive, and effective.
MediQuills welcomes ECHA’s standalone regulation as a step toward unifying chemical assessments and strengthening scientific committees. We recommend public-facing communication, multilingual non-technical summaries, transparency in scientific methods like NAMs, and youth engagement programs. These measures will build trust, improve chemical literacy, and prepare the next generation of researchers for responsible innovation.
The UN’s call for input on disability-inclusive infrastructure highlights the urgent need for accessible housing and transport. MediQuills emphasizes integrating assistive and adaptive technologies into design and policy, ensuring that people with disabilities can access environments safely and independently. Key recommendations include cross-sector collaboration, universal design standards, technology-enabled mobility solutions, and inclusive decision-making processes. Implementing these measures will strengthen accessibility, equity, and participation for all.
The EU’s European Research Area (ERA) Act aims to revitalize Europe’s research sector, which has historically suffered from underinvestment and a shortage of STEM professionals. MediQuills emphasizes supporting recombinant DNA (mRNA) technology to streamline vaccine development and accelerate public health solutions. Key recommendations include modernizing regulatory pathways, funding mRNA vaccine research, moderating GMO regulations, fostering public-private partnerships, enabling flexible manufacturing, and expanding workforce training. Together, these steps can strengthen Europe’s scientific infrastructure, advance innovation, and save lives.
MediQuills highlights the EU expert panel on orphan and pediatric devices as a key step to improve treatments for children with rare diseases. We recommend integrating recombinant biotechnology into devices, creating dedicated pediatric streams, updating risk frameworks, funding biomanufacturing, fostering collaboration, and ensuring ethical pediatric trials. These measures could advance life-saving therapies and support historically underserved patients.
MediQuills highlights the EU expert panel on orphan and pediatric devices as a key step to improve treatments for children with rare diseases. We recommend integrating recombinant biotechnology into devices, creating dedicated pediatric streams, updating risk frameworks, funding biomanufacturing, fostering collaboration, and ensuring ethical pediatric trials. These measures could advance life-saving therapies and support historically underserved patients.
MediQuills recognizes the EU’s Delegated Regulation on nine synthetic cathinone and amphetamine precursors as a crucial step to combat rising illicit stimulant production in Europe. These substances are easy to synthesize and widely diverted, posing significant public health risks. At the same time, the same precursors are essential for legitimate pharmaceutical manufacturing, analytical labs, and research. Medicines like bupropion and tolperisone rely on these intermediates, and laboratories use them as reference standards for accurate diagnostics and monitoring.
MediQuills welcomes the EU’s 2025 amendment to Directive 2004/37/EC, which updates occupational exposure limits (OELs) and adds new carcinogenic, mutagenic, and reprotoxic substances to protect workers across Europe. This initiative, known as CMRD 6, aligns with the EU’s Health and Safety Strategic Framework (2021–2027) and “Europe’s Beating Cancer Plan,” emphasizing prevention, transparency, and harmonized standards. To strengthen the regulation, MediQuills recommends: transparent publication of scientific justifications, flexible compliance pathways with interim benchmarks, dedicated support for SMEs, regular five-year OEL reviews via delegated acts, and alignment with sustainability goals. These steps would protect workers, maintain industrial feasibility, and encourage innovation while ensuring consistent safety across the EU.
All you have to do is join Mediquills by creating or joining a chapter
Learn about our plans to spread medical awareness to the country of Zambia in Africa
In many parts of Zambia, teaching children about basic medical knowledge can be life-changing rather than just informative. When kids understand simple ideas like how germs spread, why clean water matters, or when to seek help for an illness, they gain tools to protect not only themselves but their families and communities as well. An engaging lesson might turn handwashing into a game, use stories to explain how malaria is prevented, or invite local health workers to share real experiences that make the information feel relevant and empowering. By introducing medical education early in a way that is practical and relatable, children in Zambia can grow up more confident in caring for their own health and more capable of building healthier communities in the future.
Donating money to support communities in Zambia allows us to turn compassion into meaningful action. Even small contributions can help fund access to clean water, medical supplies, school resources, and nutrition programs that make a real difference in people’s daily lives. We at Mediquills plan to donate money to help those in Zambia. When we give, we’re not just sending money—we’re investing in healthier children, stronger families, and opportunities that can break cycles of poverty. Knowing that our support can help a clinic stay open, a child stay in school, or a village gain essential resources makes donating to Zambia a powerful reminder that generosity, no matter the size, has the ability to create lasting change.
Donating money to support communities in Zambia allows us to turn compassion into meaningful action. Even small contributions can help fund access to clean water, medical supplies, school resources, and nutrition programs that make a real difference in people’s daily lives. When we give, we’re not just sending money—we’re investing in healthier children, stronger families, and opportunities that can break cycles of poverty. Knowing that our support can help a clinic stay open, a child stay in school, or a village gain essential resources makes donating to Zambia a powerful reminder that generosity, no matter the size, has the ability to create lasting change.
